Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121205 | 0.82 | USP2 (0.54) | SMN1; SMN2NPC1GAAHTTMAPT | |
| SCHEMBL18701517 | 0.79 | RAB9A (0.50) | SMN1; SMN2HDAC5L3MBTL1KMT2ARAB9A | |
| SCHEMBL12660894 | 0.78 | CYP3A4 (0.55) | LMNAL3MBTL1KMT2ARAB9AMEN1 | |
| SCHEMBL21324846 | 0.78 | MEN1 (0.61) | SMN1; SMN2MAPTGPR84L3MBTL1KMT2A | |
| SCHEMBL18701579 | 0.75 | LMNA (0.49) | SMN1; SMN2GAAMAPTLMNACYP1A2 | |
| SCHEMBL18035965 | 0.73 | GPR84 (0.48) | MAPTHDAC5LMNAALOX15GPR84 | |
| SCHEMBL5935763 | 0.73 | — | — | |
| SCHEMBL803563 | 0.71 | PKM (0.54) | SMN1; SMN2NPC1GAAHTTMAPT | |
| SCHEMBL12661088 | 0.71 | L3MBTL1 (0.42) | SMN1; SMN2GAAMAPTLMNAMAPK1 | |
| SCHEMBL11782200 | 0.70 | ALDH1A1 (0.51) | SMN1; SMN2HTTMAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-20140005232-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476268-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8436023-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | SMN1; SMN2 1483/4885NPC1 168/4885GAA 164/4885 |
| US-20120263712-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | SMN1; SMN2 4449/4885NPC1 1603/4885GAA 710/4885 |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | SMN1; SMN2 4449/4885NPC1 1603/4885GAA 710/4885 |
| US-20140005232-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PDPK1, MTOR, PIK3C2A | SMN1; SMN2 1614/4885NPC1 1206/4885GAA 859/4885 |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | SMN1; SMN2 4230/4885NPC1 939/4885GAA 3576/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | SMN1; SMN2 4292/4885NPC1 500/4885GAA 383/4885 |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | SMN1; SMN2 3322/4885NPC1 970/4885GAA 3256/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | SMN1; SMN2 2655/4885NPC1 2977/4885GAA 4235/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | SMN1; SMN2 1483/4885NPC1 168/4885GAA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.